Dianthus Therapeutics (DNTH) Jefferies Global Healthcare Conference 2026 summary

Strategic program updates

• Lead asset claseprubart is advancing in three neuromuscular indications: myasthenia gravis (MG), CIDP, and MMN, with de-risked profiles and focus on rapid, high-quality execution toward approval.

• Phase III MG trial will start imminently, testing two dosing regimens, with data expected in the second half of 2028; QMG cutoff criteria added to better control placebo response.

• CIDP pivotal trial amended for faster execution: 600 mg dose arm removed, part A to B ratio increased from 40% to 50%, reflecting robust interim efficacy.

• MMN phase II data readout expected in Q4 2024, targeting a multibillion-dollar U.S. market with high unmet need and limited competition.

• DNTH212, a bifunctional fusion protein, prioritized for Sjögren's, SLE, and DM, with phase I healthy volunteer data expected in the second half of 2024.

Clinical trial design and competitive positioning

• CIDP trial design recruits all patient types and avoids placebo in part A, accelerating enrollment and offering a patient-friendly approach compared to competitors.

• Claseprubart offers less patient burden with biweekly injections versus competitors requiring more frequent dosing.

• MMN program leverages superior classical pathway inhibition potency versus competitors, with sub-Q dosing and anticipated safety advantages.

• MG market penetration expected to grow, with less than 20% of patients currently on biologics; claseprubart positioned as a safer, more convenient alternative.

• Commercial infrastructure is being built to support all three neuromuscular indications, maximizing synergies.

Market outlook and catalysts

• MMN market estimated at $800 million in IVIg sales, with potential to expand to several billion dollars as awareness and diagnosis improve.

• Key upcoming catalysts: phase II MMN data and DNTH212 phase I data in H2 2024, plus competitor readouts from Empasiprubart and riliprubart over the next 12 months.

• Cash position of $1.2 billion extends runway into 2030, supporting advancement through major clinical milestones.

• Anticipated shifts in treatment landscape for CIDP and MMN as new data from competitors and internal programs emerge.

• Regulatory alignment achieved for pivotal studies, with no gating factors for MG phase III initiation.